Bortezomib treatment sensitizes oncolytic HSV-1 treated tumors to NK cell immunotherapy

BACKGROUND: Both the proteasome inhibitor bortezomib and an oncolytic herpes simplex virus-1 (oHSV) expressing GMCSF are currently FDA-approved. While proteasome blockade can increase oHSV replication, immunological consequences and consequent immunotherapy potential are unknown. In this study, we i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Yoo, Ji Young, Jaime-Ramirez, Alena Cristina, Bolyard, Chelsea, Dai, Hongsheng, Nallanagulagari, Tejaswini, Wojton, Jeffrey, Hurwitz, Brian S., Relation, Theresa, Lee, Tae Jin, Lotze, Michael T, Yu, Jun-Ge, Zhang, Jianying, Croce, Carlo M., Yu, Jianhua, Caligiuri, Michael A., Old, Matthew, Kaur, Balveen
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5093037/
https://ncbi.nlm.nih.gov/pubmed/27390350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1003
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi